Jun 09, 2023
|
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
|
|
Jun 09, 2023
|
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
|
|
Jun 08, 2023
|
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
May 30, 2023
|
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
|
|
May 03, 2023
|
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
|
|
May 01, 2023
|
Vertex Reports First Quarter 2023 Financial Results
|
|
Apr 27, 2023
|
Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years Old
|
|
Apr 26, 2023
|
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
|
|
Apr 25, 2023
|
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
|
|
Apr 10, 2023
|
Vertex to Announce First Quarter 2023 Financial Results on May 1
|
|
Apr 03, 2023
|
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Mar 27, 2023
|
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
|
|
Mar 16, 2023
|
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
|
|
Mar 09, 2023
|
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
|
|
Feb 21, 2023
|
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
|
|
Feb 07, 2023
|
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
|
|
Jan 17, 2023
|
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
|
|
Jan 04, 2023
|
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
|
|
Dec 12, 2022
|
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
|
|
Dec 10, 2022
|
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
|
|